<DOC>
	<DOCNO>NCT01681264</DOCNO>
	<brief_summary>Dual medication ( guanfacine morphine ) standard treatment chronic pain .</brief_summary>
	<brief_title>Effect Guanfacine Opioid-induced Hyperalgesia ( OIH ) Tolerance</brief_title>
	<detailed_description>This aim propose guanfacine would useful drug deter Opioid-Induced Hyperalgesia ( OIH ) combine opioid ( morphine ) chronic pain management .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Inclusion Criteria 1865 year old Chronic neck back pain condition least 3 month VAS score 48 Has take opioid last 3 month Has take guanfacine ( alpha2AR agonist ) last 6 month Exclusion Criteria Sensory deficit site QST , peripheral neuropathy Allergic severe adverse reaction study medication ( i.e . opioids , guanfacine , lactose , vitamin B2 a.k.a . riboflavin ) Can tolerate study drug ' maximum dos Takes vitamin B2 &gt; 1.6mg/day study Pregnant breastfeed Pending litigation Diagnosed Raynaud 's syndrome Has chronic pain condition fibromyalgia joint osteoarthritis predominant back neck pain regard intensity ( VAS ) Has know preexist cardiovascular disease ( i.e . arrhythmia prolong QT interval &gt; 440ms ) , cerebrovascular disease , hepatic renal impairment , CNS condition , metabolic condition , history syncope Hypotension ( SBP &lt; 90 mmHg DBP &lt; 60 mmHg female SBP &lt; 100 mmHg DBP &lt; 60 mmHg male ; measure sit position ) bradycardia ( rest heart rate &lt; 60 bpm ) Subjects antihypertensive drug ( e.g. , betablocker ) result hypotension and/or bradycardia define Tests positive nonstudy opioids , illicit drug , marijuana , nonprescribed drug Major psychiatric disorder require hospitalization past 6 month : major depression , bipolar disorder , schizophrenia , anxiety disorder , psychotic disorder Currently treatment program alcohol drug abuse , currently methadone buprenorphine ( i.e . suboxone , subutex ) treatment addiction , stimulant treatment ADHD History substance alcohol abuse ( meet DSM IV criterion ) per medical record subject admission Subjects medication serve CYP3A4/5 inhibitor CYP3A4 inducer include , limited , valproic acid , macrolide antibiotic , antifungal drug , St. John wort , ACE inhibitor , nefazodone ( antidepressant ) , calcium channel blocker , H2receptor antagonists , antiHIV AIDS drug , antiepileptic drug Subjects medication ligands alpha2adrenergic receptor include antipsychotic drug ( e.g . clozapine ) tricyclic tetracyclic antidepressant ( e.g . imipramine , mirtazapine , mianserin ) . Any medication take subject enrollment review regard compatibility guanfacine morphine well possible confound side effect . In addition , subject warn side effect morphine sedation , respiratory depression enrollment . Subjects allowed take nonopioid pain medication except gabapentinoids amitriptyline/nortriptyline far medication incompatibility morphine guanfacine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Pain Management</keyword>
	<keyword>Back pain</keyword>
	<keyword>Neck pain</keyword>
</DOC>